6533b85dfe1ef96bd12be923
RESEARCH PRODUCT
Seroprevalence of SARs-CoV-2 among the staff and patients of a French cancer centre after first lockdown: the canSEROcov study
Laurent ArnouldJulie VincentElise BallotVincent GoussotCléa FraisseCharles CoutantAnne-laure Simonet-lammJean-david FumetEmilie RedersdorffNathalie BremaudSiavoshe AyatiAdele CueffFrançois GhiringhelliSylvie ZanettaCaroline TruntzerSilvia IlieDidier MayeurRoxana HanuBruno CoudertAlice HervieuSylvain LadoireAurélie LagrangeAurélie BertautNils MartinCoureche KaderbhaiLeila Bengrine-lefevreIrina MaziluLaure FavierIsabelle DesmoulinsRémi PalmierAudrey Hennequinsubject
0301 basic medicineMaleCancer ResearchSerology0302 clinical medicineHygieneSeroepidemiologic StudiesEpidemiologyMedicineProspective cohort studyChildmedia_commonOriginal ResearchAged 80 and overserodiagnosisseroprevalenceSocial distanceMiddle AgedSerologyOncology030220 oncology & carcinogenesisChild PreschoolCarrier StateFemaleFrancemedicine.symptomAdultmedicine.medical_specialtyAdolescentmedia_common.quotation_subjectHealth PersonnelSARS-COV-2Cancer Care FacilitiesAsymptomaticCOVID-19 Serological Testingstaff03 medical and health sciencesYoung AdultSeroprevalenceHumansAntibodyAgedbusiness.industryhealthcare workersCancerCOVID-19cancer centerCancer patientsmedicine.diseasePersonnel Hospital030104 developmental biologyFamily medicinebusinessdescription
Abstract Background In view of the potential gravity of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection for patients with cancer, epidemiological data are vital to assess virus circulation among patients and staff of cancer centres. We performed a prospective study to investigate seroprevalence of SARS-CoV-2 antibodies among staff and patients with cancer at a large cancer centre, at the end of the period of first national lockdown in France and to determine factors associated with the risk of SARS-CoV-2 infection. Methods After the first lockdown, all medical and non-medical staff, as well as all patients attending the medical oncology department were invited to undergo serological testing for SARS-CoV-2 between 11 May and 30 June 2020. All participants were also invited to complete a questionnaire collecting data about their living and working conditions, and for patients, medical management during lockdown. Findings A total of 1,674 subjects (663 staff members, 1011 patients) were included. Seroprevalence was low in both staff (1.8%) and patients (1.7%), despite more features of high risk for severe forms among patients. None of the risk factors tested in our analysis (working or living conditions, comorbidities, management characteristics during lockdown) was found to be statistically associated with seroprevalence in either staff or patients. There was no significant difference in the proportion of symptomatic and asymptomatic subjects between staff and patients. Only fever, loss of smell, and loss of taste were significantly more frequent among seropositive patients, in both staff and patients. Interpretation We report very low seroprevalence of antibodies against SARS-CoV-2 in the staff (caregiving and non-caregiving) and patients of a large cancer care centre in which strict hygiene, personal protection, and social distancing measures were implemented.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2021-02-01 | European Journal of Cancer |